Atea Pharmaceuticals Inc —— 资产负债表 (NASDAQ:AVIR) | MetaTrader

展开完整图表

Financials

概览声明统计

每季度年度

总资产 863.63 M772.89 M666.71 M594.97 M464.67 M315.22 M 负债总额 315.83 M62.81 M26.14 M39.78 M25.8 M39.78 M 权益总额 547.8 M710.08 M640.57 M555.19 M438.87 M275.43 M 负债及股东权益总额 863.63 M772.89 M666.71 M594.97 M464.67 M315.22 M 总债务 —————— 净债务 ——————

新闻

Top 2 Health Care Stocks That May Fall Off A Cliff This Month - Arcellx (NASDAQ:ACLX), Atea Pharmaceuticals (NASDAQ:AVIR)

Atea Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:AVIR) 2026-03-05

Atea Pharmaceuticals, Inc. (AVIR) Q4 2025 Earnings Call Transcript

Atea 2025年第四季度业绩:关键HCV三期数据将于2026年中期公布

Atea Q4 2025 slides: pivotal HCV Phase 3 data due mid-2026

Atea Pharmaceuticals第四季度每股亏损超预期但股价上涨

Earnings call transcript: Atea Pharmaceuticals Q4 2025 sees stock rise despite EPS miss

Atea Pharmaceuticals, Inc. (AVIR) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow (NASDAQ:AVIR) 2026-01-19

Atea Pharmaceuticals, Inc. (AVIR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Atea公司丙型肝炎治疗方案的三期临床试验结果预计2026年中期公布

Atea’s HCV treatment regimen phase 3 results expected mid-2026

Atea Pharmaceuticals: Best-In-Class HCV Cure With Pivotal Readouts In 2026 (NASDAQ:AVIR)